A novel approach to glaucoma treatment
Previously, the treatment algorithm for glaucoma relied on medical therapy at one end of the spectrum through to invasive procedures such as trabeculectomy at the other. Now, through close collaboration with teaching institutions, researchers and ophthalmic physicians, Nova Eye Medical is introducing a comprehensive portfolio of novel glaucoma treatment options which span the entire disease process – enabling physicians to intervene earlier, and more often, in the treatment of glaucoma.
On 30 June 2020, the Company completed the divestment of the Ellex Lasers & Ultrasound business to Lumibird Group SA. Today, Nova Eye Medical has a unique opportunity to leverage its platform technologies to build a comprehensive portfolio of novel glaucoma treatment technologies and devices. It also has an opportunity to advance the commercialization of the 2RT™ project.
Latest ASX Announcements
See all2024 AGM Presentation
ASX Announcement General iTrack Molteno3 AlphaRET
21 Nov, 2024
September 2024 Quarterly Activities Report and Appendix 4C
ASX Announcement General iTrack Molteno3 AlphaRET
31 Oct, 2024
Notice of Annual General Meeting 2024
ASX Announcement General iTrack Molteno3 AlphaRET
18 Oct, 2024
Quick Links
Send an enquiry
For investor enquires please contact:
Mark Flynn
Nova Eye Medical Limited
W +61 416 068 733
mflynn@nova-eye.com
This website uses cookies to ensure you get the best experience on our website.
The cookies do not store any personalised information. Learn More
The cookies do not store any personalised information. Learn More